Fierce Biotech May 16, 2024
Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology meds including a phase 1-ready asset that targets TSLP.
The new acquisition announced Thursday adds depth to J&J’s immunology roster, with a lead asset “ready to enter phase 1 development,” according to the pharma giant. That med, PX128, is a bispecific antibody targeting both IL-13 and the IL-2-like cytokine TSLP aimed at patients with atopic dermatitis (AD) and severe asthma.
Pharma and investors alike have pounced on promising TSLP-targeting biotechs. On Wednesday, Uniquity Bio unveiled with $300 million from Blackstone’s life science arm to advance its anti-TSLP candidate into phase 2 studies. And Aiolos Bio unveiled with over $200...
Today's Sponsors
Today's Sponsor